´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á ½ÃÀå : Áúº´ À¯Çüº°, ¾à¹° Á¾·ùº°, À¯Åë ä³Îº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Diabetic Neuropathy Treatment Market, By Disease Type, By Drug Class, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1536675
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 288 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,518,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,464,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,855,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á ½ÃÀå ±Ô¸ð´Â 2023³â 43¾ï 9,032¸¸ ´Þ·¯·Î 2024³âºÎÅÍ 2032³â±îÁö CAGR 8.10%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á ½ÃÀå - ½ÃÀå ¿ªÇÐ

´ç´¢º´ Ä¡·áÀÇ Áø´Ü ±â¼ú Çâ»ó°ú Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÌ ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î Àü¸Á

´ç´¢º´, ƯÈ÷ Á¦ 2Çü ´ç´¢º´ÀÇ Àü ¼¼°è À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ´ç´¢º´ ȯÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ´ç´¢º´¼º ½Å°æº´Áõ°ú °°Àº ÇÕº´Áõ¿¡ ´ëÇÑ È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Áø´Ü ±â¼úÀÇ ¹ßÀü°ú ÀνÄÀÇ °³¼±Àº ´ç´¢º´¼º ½Å°æº´ÁõÀÇ Á¶±â ¹× Á¤È®ÇÑ Áø´ÜÀ¸·Î À̾îÁý´Ï´Ù. Á¶±â Áø´ÜÀÌ ´õ ³ªÀº °ü¸®¿Í Ä¡·á ¼º°ú·Î À̾îÁö´Â °æ¿ì°¡ ¸¹±â ¶§¹®¿¡ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½ÅÈï ½ÃÀåÀÇ ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í ÀÇ·á ÀÎÇÁ¶ó °³¼±Àº ´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

½Å¾à, »ý¹°ÇÐÀû Á¦Á¦, ÀÇ·á±â±â µî »õ·Î¿î Ä¡·á¹ý ¹× Ä¡·á¹ý ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡°¡ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¾à¹°Àü´Þ ½Ã½ºÅÛ ¹× Ä¡·á Á¢±Ù ¹æ½ÄÀÇ Çõ½ÅÀº Ä¡·á ¿É¼ÇÀ» ³ÐÈ÷°í ÀÖ½À´Ï´Ù. ´ç´¢º´ ¿¬±¸ ¹× Ä¡·á¿¡ ´ëÇÑ Á¤ºÎÀÇ ³ë·Â°ú ÀÚ±Ý Áö¿ø, ´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á¿¡ ´ëÇÑ À¯¸®ÇÑ »óȯ Á¤Ã¥Àº ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ƯÁ¤ ½Å°æº´Áõ¼º ÅëÁõ °æ·Î¸¦ Ç¥ÀûÀ¸·Î »ï°Å³ª ´õ ³ªÀº È¿´É ¹× ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» Á¦°øÇÏ´Â »õ·Î¿î ¾à¹° ¹× Ä¡·á¹ýÀÇ ½ÃÀå µµÀÔÀº ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀÔ´Ï´Ù.

´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®ÀÇ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032) µ¿¾È ¿¬Æò±Õ ¾à 8.10%ÀÇ CAGR·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Áúº´ À¯Çüº° ºÎ¹®¿¡¼­´Â ¸»ÃʽŰ溴ÁõÀÌ °¡Àå ÈçÇÑ ÇüÅÂÀÇ ´ç´¢º´¼º ½Å°æº´Áõ Áß ÇϳªÀ̱⠶§¹®¿¡ 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµÆ½À´Ï´Ù.

¾à¹° Á¾·ùº°·Î´Â ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦(NSAIDs)°¡ 2023³â ÁÖ¿ä ¾àǰ Á¾·ù·Î ²ÅÇû½À´Ï´Ù.

À¯Åë ä³Îº°·Î´Â º´¿ø ¾à±¹¿¡¼­ÀÇ Åõ¾àÀÌ ¸¹±â ¶§¹®¿¡ 2023³â À¯Åë ä³ÎÀº º´¿ø ¾à±¹ÀÌ 1À§¸¦ Â÷ÁöÇß½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ ´ç´¢º´ Ä¡·á¸¦ À§ÇÑ ÀÇ·á ÀÎÇÁ¶ó°¡ ¹ß´ÞÇØ 2023³â ¸ÅÃâÀ» ÁÖµµÇß½À´Ï´Ù.

´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼®:

¼¼°è ´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á ½ÃÀåÀº Áúº´ À¯Çü, ¾à¹° Á¾·ù, À¯Åë ä³Î, Áö¿ªº°·Î ºÐ·ùµË´Ï´Ù.

Áúȯ À¯Çüº°·Î º¸¸é ¸»ÃʽŰæÀå¾Ö, ÀÚÀ²½Å°æÀå¾Ö, ±ÙÀ§ºÎ½Å°æÀå¾Ö, ±¹¼Ò½Å°æÀå¾Ö µî 4°¡Áö·Î ³ª´¹´Ï´Ù. ¸»ÃʽŰ溴Áõ ºÐ¾ß°¡ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. °í·ÉÃþÀÇ ³ôÀº ´ç´¢º´ À¯º´·ü·Î ÀÎÇØ ÀÌ ºÎ¹®ÀÇ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¾à¹° Á¾·ù¿¡ µû¶ó ½ÃÀåÀº ĸ»çÀ̽Å, ¿ÀÇÇ¿ÀÀ̵å, ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦(NSAIDs), ±âŸ 4°¡Áö·Î ºÐ·ùµË´Ï´Ù. ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦(NSAIDs) ºÎ¹®ÀÌ ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿ÀÇÇ¿ÀÀÌµå ºÐ¾ß´Â ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿ÀÇÇ¿ÀÀ̵å´Â °­·ÂÇÑ ÁøÅëÁ¦À̸ç, º¸´Ù È¿°úÀûÀÎ ÁøÅë È¿°ú¸¦ °¡Á®¿Ã ¼ö ÀÖ½À´Ï´Ù.

½ÃÀåÀº À¯Åë ä³Î¿¡ µû¶ó º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ±âŸ ¼¼ °¡Áö·Î ºÐ·ùµË´Ï´Ù. º´¿ø ¾à±¹ ºÎ¹®ÀÌ ½ÃÀåÀ» Áö¹èÇϰí ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È ³ôÀº ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º´¿ø ¾à±¹Àº ÀǾàǰÀ» °ü¸®Çϱâ À§ÇÑ ÅëÇÕ ½Ã½ºÅÛÀ» °®Ãß°í ÀÖ¾î 󸮰¡ ¿ëÀÌÇϱ⠶§¹®¿¡ µµÀÔÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á ½ÃÀå - Áö¸®Àû ÀλçÀÌÆ®

Áö¸®ÀûÀ¸·Î ÀÌ ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡ ºÐÆ÷µÇ¾î ÀÖ½À´Ï´Ù. ¹Ì±¹À» Áß½ÉÀ¸·Î ÇÑ ºÏ¹Ì´Â ³ôÀº ´ç´¢º´ À¯º´·ü°ú ¹ß´ÞµÈ ÀÇ·á ÀÎÇÁ¶ó·Î ÀÎÇØ Àü ¼¼°è ´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á ½ÃÀå¿¡¼­ Å« ºñÁßÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. Áß±¹, Àεµ µî ¾Æ½Ã¾ÆÅÂÆò¾çÀº ´ç´¢º´ À¯º´·ü Áõ°¡¿Í ÀÇ·á ÀÎÇÁ¶ó °³¼±À¸·Î ÀÎÇØ ´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á ½ÃÀåÀÌ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á ½ÃÀå - °æÀï ÇöȲ:

´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á ½ÃÀåÀº ¸¹Àº ±â¾÷µéÀÌ ´ç´¢º´ Ä¡·á ¼Ö·ç¼ÇÀ» °³¹ß ¹× Á¦°øÇÏ´Â µ¥ °ü¿©Çϰí ÀÖ¾î °æÀïÀÌ Ä¡¿­ÇÕ´Ï´Ù. ½ÃÀå ÁøÀÔ ±â¾÷µéÀº ´ç´¢º´¼º ½Å°æº´Áõ°ú °ü·ÃµÈ ƯÁ¤ ÅëÁõ °æ·Î¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â »õ·Î¿î Á¦Á¦ ¹× Ç¥Àû Ä¡·áÁ¦¿Í °°Àº »õ·Î¿î ¾à¹°À» °³¹ßÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ´ç´¢º´ À¯º´·üÀÇ Áõ°¡¿Í ÀÇ·á ÀÎÇÁ¶óÀÇ È®ÀåÀ¸·Î ÀÎÇØ ±â¾÷µéÀº ¾Æ½Ã¾ÆÅÂÆò¾ç ¹× ¶óƾ¾Æ¸Þ¸®Ä« µî ½ÅÈï ½ÃÀå¿¡ ´õ ¸¹Àº °ü½ÉÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ´ç´¢º´¼º ½Å°æº´Áõ Ä¡·áÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á »ê¾÷ ¿¬±¸

Á¦5Àå ´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå ´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á ½ÃÀå »óȲ

Á¦7Àå ´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á ½ÃÀå - Áúȯ À¯Çüº°

Á¦8Àå ´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á ½ÃÀå - ¾à¹° Á¾·ùº°

Á¦9Àå ´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á ½ÃÀå - À¯Åë ä³Îº°

Á¦10Àå ´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á ½ÃÀå - Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® - ´ç´¢º´¼º ½Å°æº´Áõ Ä¡·á ¾÷°è

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Diabetic Neuropathy Treatment Market size was valued at USD 4,390.32 Million in 2023, expanding at a CAGR of 8.10% from 2024 to 2032.

Diabetic neuropathy is a type of nerve damage that can occur in people with diabetes, usually because of prolonged high blood sugar levels. Treatment typically focuses on managing symptoms and preventing further nerve damage.

Diabetic Neuropathy Treatment Market- Market Dynamics

Improved diagnostic techniques in diabetes treatment and innovative therapies are expected to propel market demand

The growing incidence of diabetes, particularly type 2 diabetes, worldwide is a key driver of the market growth. As the number of diabetes patients increases, so does the demand for effective treatments for complications such as diabetic neuropathy. Advances in diagnostic technologies and increased awareness lead to earlier and more accurate diagnosis of diabetic neuropathy. Early diagnosis often leads to better management and treatment outcomes, increasing the demand for therapies. Higher healthcare spending and improved healthcare infrastructure in emerging markets contribute to the growth of the diabetic neuropathy treatment market.

Increasing investment into research & new treatments and therapies, including novel pharmaceuticals, biologics, and medical devices, contributes to market growth. Innovations in drug delivery systems and therapeutic approaches enhance treatment options. Government initiatives and funding for diabetes research and treatment, as well as favorable reimbursement policies for diabetic neuropathy therapies, support market growth. The introduction of new drugs and therapies into the market, including those targeting specific neuropathic pain pathways or providing better efficacy and safety profiles, drives market growth.

Diabetic Neuropathy Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.10% over the forecast period (2024-2032)

Based on Disease Type segmentation, the peripheral neuropathy segment was predicted to show maximum market share in the year 2023, as it is one of the most common forms of diabetic neuropathy.

Based on Drug Class segmentation, the non-steroidal anti-inflammatory drugs (NSAIDs) segment was the leading Drug Class in 2023, due to its affordability in the market.

Based on Distribution Channel segmentation, the hospital pharmacies segment was the leading Distribution Channel in 2023, owing to high medication at hospital pharmacies.

On the basis of region, North America was the leading revenue generator in 2023, owing to the presence of developed healthcare infrastructure for diabetic treatment.

Diabetic Neuropathy Treatment Market- Segmentation Analysis:

The Global Diabetic Neuropathy Treatment Market is segmented on the basis of Disease Type, Drug Class, Distribution Channel, and Region.

The market is divided into four categories based on Disease Type: peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. The peripheral neuropathy segment dominates the market. The high prevalence of diabetes among old adults is boosting segment demand.

The market is divided into four categories based on Drug Class: capsaicin, opioid, Non-Steroidal Anti-inflammatory Drugs (NSAIDs), and others. The Non-Steroidal Anti-inflammatory Drugs (NSAIDs) segment is projected to hold the largest share of the market. The opioid segment is estimated to grow at the fastest rate over the forecast period. Opioids are potent analgesics that can provide more effective pain relief.

The market is divided into three categories based on Distribution channels: hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment dominates the market and is expected to maintain its high dominance during the forecast period. Hospital pharmacies have an integrated system for managing medications, which makes it easier to process and hence have greater adoption.

Diabetic Neuropathy Treatment Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America, predominantly the United States, holds a significant share of the global diabetic neuropathy treatment market due to a high prevalence of diabetes and advanced healthcare infrastructure. The Asia-Pacific region, including countries like China and India, is experiencing rapid growth in the diabetic neuropathy treatment market due to rising diabetes rates and improving healthcare infrastructure.

Diabetic Neuropathy Treatment Market- Competitive Landscape:

The diabetic neuropathy treatment market is moderately competitive, with numerous companies involved in developing and offering diabetic treatment solutions. Market players are working on novel drugs targeting specific pain pathways associated with diabetic neuropathy including new formulations and targeted therapies. Companies are increasingly focusing on emerging markets such as Asia-Pacific and Latin America due to the rising prevalence of diabetes and expanding healthcare infrastructure.

Recent Developments:

In December 2023, Vertex Pharmaceuticals got FDA approval for CRISPR-based gene editing therapy, a strategic move which focuses on the development of non-opioid pain management drugs.

In July 2023, Asprius Lifesciences, an Indian pharmaceutical company, has launched a treatment for Diabetic Neuropathy, a condition causing nerve damage.

In 2022, Axovant Gene Therapies is exploring advanced treatments including gene and cell therapies for neurological conditions.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET KEY PLAYERS

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2019-2032

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019-2032

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019-2032

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

Table of Contents

1. Diabetic Neuropathy Treatment Market Overview

2. Executive Summary

3. Diabetic Neuropathy Treatment Key Market Trends

4. Diabetic Neuropathy Treatment Industry Study

5. Diabetic Neuropathy Treatment Market: COVID-19 Impact Analysis

6. Diabetic Neuropathy Treatment Market Landscape

7. Diabetic Neuropathy Treatment Market - By Disease Type

8. Diabetic Neuropathy Treatment Market - By Drug Class

9. Diabetic Neuropathy Treatment Market - By Distribution Channel

10. Diabetic Neuropathy Treatment Market- By Geography

11. Key Vendor Analysis- Diabetic Neuropathy Treatment Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â